Notwithstanding encouraging clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial difficulty from pharmacy benefit managers. Such organizations are typically building limitations to reimbursement, such as high pr